SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 9 of 23
Word Count: 1419
Character Count: 8937

Document Content:

documents that we file with the SEC and that are incorporated by reference in this prospectus supplement will automatically update and supersede information contained in this prospectus supplement, including information in previously filed documents or reports that have been incorporated by reference in this prospectus supplement, to the extent the new information differs from or is inconsistent with the old information. We have filed or may file the following documents with the SEC and they are incorporated herein by reference as of their respective dates of filing: ● Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 31, 2025; ● Those portions of our Definitive Proxy Statement on Schedule 14A for our 2025 Annual Meeting of Stockholders filed with the SEC on April 28, 2025 that are incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2024;

●	Quarterly Reports on Form 10-Q
for the fiscal quarters ended March 31,
2025 , June 30, 2025 and September 30, 2025, respectively, filed on May 15, 2025 , August 14,
2025 , and November 13, 2025 , respectively;

●	Current Reports on Form 8-K (excluding
any reports or portions thereof that are deemed to be furnished and not filed) filed on  March 31,
2025 , June 4,
2025 , June 12,
2025 , June 18,
2025 , August 27, 2025 and September 22, 2025 ; and

●	Our registration statement on  Form 8-A  filed
on October 21, 2024.

We also incorporate by reference
all documents we file under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any portions of filings that are furnished
rather than filed pursuant to Items 2.02, 7.01 or 9.01 of a Current Report on Form 8-K) (a) after the initial filing date of the registration
statement of which this prospectus supplement is a part and before the effectiveness of the registration statement and (b) after the effectiveness
of the registration statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus
supplement have been sold or that deregisters the securities covered by this prospectus supplement then remaining unsold. The most recent
information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing
will be deemed to be a part of this prospectus supplement, commencing on the date on which the document is filed.

Any statement contained in
a document incorporated or deemed to be incorporated by reference in this prospectus supplement shall be deemed modified, superseded or
replaced for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement, or in any
subsequently filed document that also is deemed to be incorporated by reference in this prospectus supplement, modifies, supersedes or
replaces such statement. Any statement so modified, superseded or replaced shall not be deemed, except as so modified, superseded or replaced,
to constitute a part of this prospectus supplement. None of the information that we disclose under Items 2.02 or 7.01 of any Current Report
on Form 8-K or any corresponding information, either furnished under Item 9.01 or included as an exhibit therein, that we may from time
to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this prospectus supplement, except as otherwise
expressly set forth in the relevant document. Subject to the foregoing, all information appearing in this prospectus supplement is qualified
in its entirety by the information appearing in the documents incorporated by reference.

You may request, orally or
in writing, a copy of these documents, which will be provided to you at no cost (other than exhibits, unless such exhibits are specifically
incorporated by reference), by writing or telephoning us at the following address:

Synergy CHC Corp.

865 Spring Street

Westbrook, Maine 04092

Information about us is also
available at our website at https://www.synergychc.com. However, the information in our website is not a part of this prospectus supplement
and is not incorporated by reference.

PROSPECTUS

Synergy CHC Corp.

Common Stock

Preferred Stock

Warrants

Debt Securities

Subscription Rights

Units

We may offer, issue and sell
from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock,
which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi)
units. The debt securities may consist of debentures, notes, or other types of debt. The debt securities, preferred stock, warrants and
subscription rights may be convertible into, or exercisable or exchangeable for, common or preferred stock or other securities of ours.
The units may consist of any combination of the securities listed above.

The aggregate public offering
price of the securities that we may offer will not exceed $100 million. We will offer the securities in an amount and on terms that market
conditions will determine at the time of the offering. Our common stock is currently listed on The Nasdaq Capital Market, or Nasdaq, under
the symbol “SNYR.” On November 20, 2025, the last reported sale price of our common stock as quoted on Nasdaq was $2.08 per
share. You are urged to obtain current market quotations of our common stock. We have no preferred stock, warrants, debt securities, subscription
rights or units listed on any market. Each prospectus supplement will indicate if the securities offered thereby will be listed on any
securities exchange.

The aggregate market value
of our outstanding common stock held by non-affiliates is $17.1 million based on 11,251,853 shares of outstanding common stock, of which
6,347,133 shares are held by non-affiliates, and a per share price of $2.69, which was the closing sale price of our common stock as quoted
on the Nasdaq Capital Market on October 22, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares
pursuant to this prospectus with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates
in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During
the 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction
I.B.6 of Form S-3.

Investing in our securities
involves risk. You should carefully consider the risks that we refer you to under the section captioned “Risk Factors” in
this prospectus on page 7 before buying our securities.

Should we offer any of the
securities described in this prospectus, we will provide you with the specific terms of the particular securities being offered in supplements
to this prospectus. You should read this prospectus and any supplement, together with additional information described under the headings
“Additional Information” and “Incorporation of Certain Information by Reference” carefully before you invest.
This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.

We may sell these securities
directly to our stockholders or to other purchasers or through agents on our behalf or through underwriters or dealers as designated from
time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement
will provide the names of the agents or underwriters and any applicable fees, commissions or discounts.

We are a “smaller reporting
company” as defined under the federal securities laws and, under applicable SEC rules, we have elected to comply with certain reduced
public company reporting and disclosure requirements.

Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is December 9, 2025.

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS	ii

PROSPECTUS SUMMARY	1

RISK FACTORS	7

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	8

USE OF PROCEEDS	9

THE SECURITIES WE MAY OFFER	10

DESCRIPTION OF CAPITAL STOCK	11

DESCRIPTION OF DEBT SECURITIES	14

DESCRIPTION OF STOCK WARRANTS	20

DESCRIPTION OF SUBSCRIPTION RIGHTS	21

DESCRIPTION OF UNITS	22

FORMS OF SECURITIES	23

PLAN OF DISTRIBUTION	25

LEGAL MATTERS	28

EXPERTS	28

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES	29

ADDITIONAL INFORMATION	30

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	31

Synergy CHC Corp. is referred
to herein as “Synergy,” “the Company,” “we,” “us” and “our,” unless the context
indicates otherwise.